Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1141-1146

  Furugaki, Koh ^a   Iwai, Toshiki ^a   Shirane, Masatoshi ^a   Kondoh, Kumiko ^a   Moriya, Yoichiro ^a   Mori, Kazushige ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Docetaxel; EGFR mutation; Epidermal growth factor receptor inhibitor; Erlotinib; KRAS mutation; Non small cell lung cancer

Indexed keywords

DOCETAXEL; ERLOTINIB; K RAS PROTEIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78149332013     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000965     Document Type: Article

References (23)

1. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small- cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
3. Davies AM, Lara PN Jr, Mack PC and Gandara DR: Docetaxel in non-small cell lung cancer: A review. Expert Opin Pharmacother 4: 553-565, 2003.
4. Dancey J and Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296-313, 2003.
5. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
6. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.
7. Tanaka T, Matsuoka M, Sutani A, et al: Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: 651-655, 2010.
8. Mounawar M, Mukeria A, Le Calvez F, et al: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67: 5667-5672, 2007.
9. Schneider CP, Heigener D, Schott-von-Romer K, et al: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: An analysis of patients from german centers in the trust study. J Thorac Oncol 3: 1446-1453, 2008.
10. Solit DB, She Y, Lobo J, et al: Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11: 1983-1989, 2005.
11. Mahaffey CM, Davies AM, Lara PN Jr, et al: Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: Rationale for pharmacodynamic separation. Clin Lung Cancer 8: 548-553, 2007.
12. Morelli MP, Cascone T, Troiani T, et al: Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16 (Suppl 4): iv61-iv68, 2005.
13. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
14. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W and Dreyling M: Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21: 524-528, 2007.
15. Lindhagen E, Eriksson A, Wickström M, et al: Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 81: 344-353, 2008.
16. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22: 7010, 2004.
17. Herbst RS, Prager D, Hermann R, et al: Tribute: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carbo-platin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899, 2005.
18. Li T, Ling Y-H, Goldman ID and Perez-Soler R: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13: 3413-3422, 2007.
19. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
20. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H and Yokota J: Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res 54: 5643-5648, 1994.
21. Badalian G, Barbai T, Raso E, Derecskei K, Szendroi M and Timar J: Phenotype of bone metastases of non-small cell lung cancer: Epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 13: 99-104, 2007.
22. Gow C-H, Chang Y-L, Hsu Y-C, et al: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20: 696-702, 2009.
23. Davies AM, Hesketh PJ, Beckett L, et al: Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. J Clin Oncol 25: 7618, 2007.